- Trial phase
- Approved
- Time to market
- Already approved and marketed since 2015; the latest label expansion was approved June 24, 2026.
- Why 4/10
- Ibrance is already approved and commercializing with no pending PDUFA or pivotal readout in the next ~12 months; the next hard catalyst is the March 2027 patent expiration, which is a commercial event rather than a regulatory binary. As a mature, declining asset at a diversified mega-cap pharma, impactScore is capped at 4 per the rubric for approved drugs with no imminent regulatory decision.
Ibrance has no upcoming PDUFA or pivotal readout in the next 12 months; the next major event is the March 2027 patent expiration, which will open the door to generic competition. Watch for Pfizer's Q4 2026 earnings (late January 2027) for the first full-quarter sales data after the June 2026 label expansion, and for any settlement or litigation updates on generic challengers.
Price Chart
Executive Summary
Ibrance (palbociclib) is Pfizer's blockbuster CDK4/6 inhibitor for hormone receptor-positive (HR+) breast cancer, first approved in 2015. It generated approximately $4.1 billion in 2025 sales, though revenue has declined for four consecutive years as competitors Kisqali (Novartis) and Verzenio (Eli Lilly) have gained ground. In June 2026, the FDA approved a new indication for Ibrance in HR+/HER2+ metastatic breast cancer maintenance based on the Phase 3 PATINA trial, making it the only CDK4/6 inhibitor approved across all HER2 statuses in HR+ disease. However, the core U.S. patent expires March 5, 2027, and Ibrance failed in early breast cancer (adjuvant setting), closing off a larger market opportunity. For a diversified mega-cap like Pfizer, Ibrance is a mature, cash-generating asset facing a patent cliff rather than a binary catalyst.
How It Works
Ibrance is a targeted oral cancer drug, not chemotherapy. It blocks two proteins called CDK4 and CDK6 that cancer cells need to divide and multiply. By inhibiting these proteins, Ibrance stops cancer cells from progressing through their growth cycle, effectively slowing or halting tumor growth. It is used specifically in hormone receptor-positive (HR+) breast cancer, often combined with hormone-blocking therapies.
Trial Status
Ibrance is FDA-approved across multiple indications in HR+ breast cancer. The most recent approval (June 2026) was based on the Phase 3 PATINA trial, which showed a statistically significant improvement in progression-free survival (44.3 vs 29.1 months median PFS) when added to anti-HER2 and endocrine therapy for HR+/HER2+ metastatic breast cancer maintenance. Ibrance failed in the adjuvant early breast cancer setting (PALLAS and PENELOPE-B trials). Pfizer is also developing a next-generation CDK inhibitor, atirmociclib, which showed positive Phase 2 results (FOURLIGHT-1) with a 40% risk reduction in disease progression.
The Two-Sided Case
Upcoming Catalysts
- March 5, 2027: U.S. patent expiration for core composition-of-matter patent (US RE47,739), enabling generic entry.
- Q4 2026 / early 2027 earnings: First full-quarter sales data following the June 2026 label expansion, indicating whether the new indication is offsetting competitive erosion.
- Potential atirmociclib (next-gen CDK inhibitor) Phase 3 readout timing and regulatory filings, though this is a separate molecule from Ibrance.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PFIZER INC 8-K PFE ·Originating report